CO2017006032A2 - Métodos para tratar la calcificación de tejidos - Google Patents

Métodos para tratar la calcificación de tejidos

Info

Publication number
CO2017006032A2
CO2017006032A2 CONC2017/0006032A CO2017006032A CO2017006032A2 CO 2017006032 A2 CO2017006032 A2 CO 2017006032A2 CO 2017006032 A CO2017006032 A CO 2017006032A CO 2017006032 A2 CO2017006032 A2 CO 2017006032A2
Authority
CO
Colombia
Prior art keywords
calcification
npp1
provides
present
tissues
Prior art date
Application number
CONC2017/0006032A
Other languages
English (en)
Inventor
Anthony Quinn
Nelson Hsia
Tayeba Khan
Kim Lynette Askew
Gregory Grabowski
Zhiliang Cheng
W Charles O'neill
Original Assignee
Alexion Pharma Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Alexion Pharma Inc filed Critical Alexion Pharma Inc
Publication of CO2017006032A2 publication Critical patent/CO2017006032A2/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/16—Hydrolases (3) acting on ester bonds (3.1)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y301/00—Hydrolases acting on ester bonds (3.1)
    • C12Y301/04—Phosphoric diester hydrolases (3.1.4)
    • C12Y301/04001—Phosphodiesterase I (3.1.4.1)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y306/00—Hydrolases acting on acid anhydrides (3.6)
    • C12Y306/01—Hydrolases acting on acid anhydrides (3.6) in phosphorus-containing anhydrides (3.6.1)
    • C12Y306/01009—Nucleotide diphosphatase (3.6.1.9), i.e. nucleotide-pyrophosphatase
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Wood Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Molecular Biology (AREA)
  • Diabetes (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Medicinal Preparation (AREA)

Abstract

RESUMEN La presente invención proporciona un método para tratar la deficiencia de NPP1 o una enfermedad asociada con NPP1 tal como la calcificación arterial idiopática infantil (IIAC), pseudoxantoma elástico, calcificación vascular en enfermedad renal crónica (VCCKD), resistencia a la insulina, raquitismo hipofosfatémico, isquemia del miocardio, calcificación de articulaciones, estrías angioides, y osificación del ligamento longitudinal posterior de la espina. La presente invención proporciona un método para tratar la calcificación de tejidos al administrar NPP1 soluble para producir un incremento transitorio en los niveles de pirofosfato en suero.
CONC2017/0006032A 2014-12-19 2017-06-16 Métodos para tratar la calcificación de tejidos CO2017006032A2 (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201462094943P 2014-12-19 2014-12-19
US201562249781P 2015-11-02 2015-11-02
PCT/US2015/066646 WO2016100803A2 (en) 2014-12-19 2015-12-18 Methods of treating tissue calcification

Publications (1)

Publication Number Publication Date
CO2017006032A2 true CO2017006032A2 (es) 2017-10-20

Family

ID=56127864

Family Applications (1)

Application Number Title Priority Date Filing Date
CONC2017/0006032A CO2017006032A2 (es) 2014-12-19 2017-06-16 Métodos para tratar la calcificación de tejidos

Country Status (14)

Country Link
US (2) US10493135B2 (es)
EP (2) EP3234116B1 (es)
JP (3) JP2018500315A (es)
KR (1) KR20170095367A (es)
CN (1) CN107109381A (es)
AU (1) AU2015364411A1 (es)
BR (1) BR112017012928A2 (es)
CA (1) CA2971414A1 (es)
CO (1) CO2017006032A2 (es)
ES (1) ES2899895T3 (es)
HK (1) HK1245662A1 (es)
MX (3) MX2017007946A (es)
RU (1) RU2770698C2 (es)
WO (1) WO2016100803A2 (es)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2956163A4 (en) * 2013-02-13 2017-03-22 Yale University Compositions and methods for treating pathological calcification and ossification
US10493135B2 (en) * 2014-12-19 2019-12-03 Alexion Pharmaceuticals, Inc. Methods of treating tissue calcification
CA3176123A1 (en) 2015-05-19 2016-11-24 Yale University Compositions for treating pathological calcification conditions, and methods using same
EP3471747A1 (en) 2016-06-16 2019-04-24 Alexion Pharmaceuticals, Inc. Methods of treating myointimal proliferation
US11390859B2 (en) 2016-08-05 2022-07-19 Yale University Compositions and methods for stroke prevention in pediatric sickle cell anemia patients
US20200263153A1 (en) * 2017-09-27 2020-08-20 Alexion Pharmaceuticals, Inc. Methods of improving cardiovascular function and treating cardiovascular disease using a recombinant ectonucleotide pyrophosphatase phosphodiesterase (npp1)
EP3790628A4 (en) * 2018-05-08 2022-03-09 Yale University COMPOSITIONS AND METHODS TO REDUCE PROGRESSION OF NEPHROLITHIASIS
CN112930397A (zh) * 2018-08-31 2021-06-08 耶鲁大学 Enpp1多肽及其使用方法
JP2022517435A (ja) * 2019-01-18 2022-03-08 イノザイム ファーマ インク． Ｅｎｐｐ１またはｅｎｐｐ３の欠乏をともなう疾患の治療
KR20230042263A (ko) * 2020-06-09 2023-03-28 이노자임 파마, 인코포레이티드 가용성 enpp1 또는 enpp3 단백질 및 이의 사용
KR20230123932A (ko) * 2020-11-19 2023-08-24 이노자임 파마, 인코포레이티드 Enpp1 결핍증 및 abcc6 결핍증의 치료

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4751180A (en) 1985-03-28 1988-06-14 Chiron Corporation Expression using fused genes providing for protein product
US4935233A (en) 1985-12-02 1990-06-19 G. D. Searle And Company Covalently linked polypeptide cell modulators
SE509359C2 (sv) 1989-08-01 1999-01-18 Cemu Bioteknik Ab Användning av stabiliserade protein- eller peptidkonjugat för framställning av ett läkemedel
US6267964B1 (en) 1989-08-01 2001-07-31 Affibody Technology Sweden Ab Stabilized protein or peptide conjugates able to bond albumin having extended biological half-lives
DK1032662T3 (da) 1997-11-07 2006-07-03 Trillium Therapeutics Inc Fremgangsmåder og sammensætninger til immunmodulation
US6272859B1 (en) 1998-10-02 2001-08-14 Caterpillar Inc. Device for controlling a variable geometry turbocharger
US7608681B2 (en) 1999-12-24 2009-10-27 Genentech, Inc. Methods and compositions for prolonging elimination half-times of bioactive compounds
AU2001239837B2 (en) 2000-02-23 2006-06-22 Pxe International, Inc. Methods and composition for diagnosing and treating pseudoxanthoma elasticum and related conditions
AU2002335930B2 (en) 2001-03-09 2005-07-28 Morphosys Ag Serum albumin binding moieties
US7858297B2 (en) 2001-12-18 2010-12-28 Centre National De La Recherche Scientifique Cnrs Chemokine-binding protein and methods of use
US7323542B2 (en) 2002-02-21 2008-01-29 University Of Virginia Patent Foundation Bone targeting peptides
AU2003210806A1 (en) 2002-03-05 2003-09-22 Eli Lilly And Company Heterologous g-csf fusion proteins
WO2004001064A2 (en) 2002-06-21 2003-12-31 Dyax Corporation Serum protein-associated target-specific ligands and identification method therefor
HUE027902T2 (en) 2004-02-09 2016-11-28 Human Genome Sciences Inc Corp Service Company Albumin fusion proteins
US20050287284A1 (en) 2004-06-28 2005-12-29 Shukla Triveni P Processed meats comprising dietary fiber gel
US20090142347A1 (en) * 2004-09-29 2009-06-04 The Burnham Institute For Medical Research Tissue-Nonspecific Alkaline Phosphatase (TNAP): a Therapeutic Target for Arterial Calcification
WO2008028977A2 (en) 2006-09-08 2008-03-13 Ablynx N.V. Serum albumin binding proteins with long half-lives
WO2012125182A1 (en) 2011-03-11 2012-09-20 Synageva Biopharma Corp Npp1 fusion proteins
EP2545080B1 (en) 2010-03-12 2017-05-10 Alexion Pharmaceuticals, Inc. Npp1 fusion proteins
EP2956163A4 (en) * 2013-02-13 2017-03-22 Yale University Compositions and methods for treating pathological calcification and ossification
US10493135B2 (en) * 2014-12-19 2019-12-03 Alexion Pharmaceuticals, Inc. Methods of treating tissue calcification
CA3176123A1 (en) 2015-05-19 2016-11-24 Yale University Compositions for treating pathological calcification conditions, and methods using same
US20180371434A1 (en) 2015-11-20 2018-12-27 Yale University Compositions for Treating Ectopic Calcification Disorders, and Methods Using Same

Also Published As

Publication number Publication date
EP3967755A1 (en) 2022-03-16
MX2022011281A (es) 2022-10-18
US10493135B2 (en) 2019-12-03
RU2017119466A (ru) 2019-01-21
EP3967755B1 (en) 2024-03-27
AU2015364411A1 (en) 2017-06-08
CN107109381A (zh) 2017-08-29
JP2018500315A (ja) 2018-01-11
CA2971414A1 (en) 2016-06-23
KR20170095367A (ko) 2017-08-22
BR112017012928A2 (pt) 2018-05-15
JP2022003048A (ja) 2022-01-11
WO2016100803A2 (en) 2016-06-23
EP3234116B1 (en) 2021-09-08
ES2899895T3 (es) 2022-03-15
RU2017119466A3 (es) 2019-12-20
USRE49529E1 (en) 2023-05-16
EP3234116A2 (en) 2017-10-25
EP3234116A4 (en) 2018-08-01
MX2023006083A (es) 2023-06-19
JP2024010052A (ja) 2024-01-23
RU2770698C2 (ru) 2022-04-21
WO2016100803A3 (en) 2016-08-04
MX2017007946A (es) 2017-09-15
US20180318400A1 (en) 2018-11-08
HK1245662A1 (zh) 2018-08-31

Similar Documents

Publication Publication Date Title
CO2017006032A2 (es) Métodos para tratar la calcificación de tejidos
BR112015009948A2 (pt) antagonistas de ativina-actriia e usos para tratamento ósseos e outros disturbios
PE20191303A1 (es) Compuestos con actividad antitumoral contra celulas cancerosas que tienen mutaciones en el exon 20 de egfr o her2
PH12017500070A1 (en) Methods of treating cancer using tigit inhibitors and anti-cancer agents
MX2021000848A (es) Compuestos y sus usos para modular la hemoglobina.
BR112016029906A2 (pt) compostos excipientes redutores de viscosidade para formulações proteicas
MX2015011769A (es) Compuestos y sus usos para modular la hemoglobina.
MX2015011509A (es) Compuestos y usos de estos para la modulacion de la hemoglobina.
BR112015006176A8 (pt) método de tratamento de câncer em um indivíduo com necessidade de tratamento
BR112017015864A2 (pt) compostos e métodos para modular a expressão de tmprss6
MX2015011445A (es) Compuestos y usos de estos para la modulacion de la hemoglobina.
AR100560A1 (es) Inhibición o regulación por disminución de la glucógeno sintasa mediante la creación de codones de terminación prematuros utilizando oligonucléotidos antisentido
BR112016022742A2 (pt) composições e métodos para modular a expressão de receptor de hormônio do crescimento
AR092899A1 (es) Uso de masitinib para el tratamiento del cancer en subpoblaciones de pacientes identificados que utilizan factores de prediccion
BR112018000468A2 (pt) 4-azaindóis substituídos e seu uso como moduladores do receptor de glun2b
EA201992707A1 (ru) Соединения и их применения для модуляции гемоглобина
GT201600084A (es) (aza) piridopirazolopirimidinonas e indazolopirimidinonas y su uso
CL2019001214A1 (es) Composición farmacéutica, métodos para tratamiento y sus usos.
MX356755B (es) Compuestos de tipo fumagilol y metodos para su elaboración y uso.
MX2017005861A (es) Metodos para el control transcripcional objetivo en regiones del super mejorador.
WO2014110353A9 (en) Notch ligand bound biocompatible substrates and their use in bone formation
BR112016018704A2 (pt) fgf-18 em procedimentos de transplante de enxerto e de engenheiramento de tecido
MX2018014129A (es) Composiciones farmaceuticas de oligomero de morfolino fosforodiamidato.
EA201491522A1 (ru) Способы лечения нарушения походки и/или равновесия у пациентов с рассеянным склерозом с использованием аминопиридина
EA201491836A1 (ru) Способы лечения рака с использованием ингибитора pi3k и ингибитора mek